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Over the last decade, the host immunity has emerged as a
critical determinant of cancer development and of
response to therapy. Great progress has been made in the
development of immunotherapies, which leverage the
patient’s immune system to reach better clinical out-
comes. Immune checkpoint inhibitors, such as anti-
CTLA-4 or anti-PD-1/PD-L1, show deep and durable
tumor responses in various indications. However,
response rates vary a lot depending on the tumor type
and remain relatively low. Scientists and clinicians are
currently struggling in the research of reliable biomarkers
to predict patient response. Studying the development
and selection of lymphocyte repertoires is essential to
understand the function of the immune system in healthy
individuals and in cancer patients. We propose an
innovative test called ImmunTraCkeR® to study T cell
immune repertoire diversity, based on the detection of
V-J rearrangements of the T cell receptor (TCR). Our
immune profiling platform allows to monitor immune
diversity in blood or tumors and to assess variations
between individuals. Past studies have shown the clinical
utility of T cell diversity and patient’s immune status in
several indications, including metastatic cancers and
infections. Here, we performed a study on healthy sub-
jects to evaluate the performances of our immune profil-
ing platform and the stability of T cell repertoire over
time. TCR diversity was assessed through the human
ImmunTraCkeR® test on genomic DNA extracted from
peripheral blood mononuclear cells, obtained from 31
healthy donors. For 4 samples, ImmunTraCkeR® was
replicated at least twice to evaluate platform perfor-
mances. In addition, day-0 and day-21 samples from
27 healthy subjects were tested in blind to further assess
ImmunTraCkeR® performances and to evaluate the
kinetics of TCR diversity. Unsupervised hierarchical clus-
tering with multiscale bootstrap resampling showed the
high repeatability of the platform and high stability of
TCR repertoire overtime in healthy subjects. Comparison
to cancer patients under treatment is currently ongoing.
Results confirm that ImmunTraCkeR® can be used as a
powerful and reliable tool to monitor kinetics of T cell
repertoire during the course of disease and/or treatment.
ImmunTraCkeR® may allow clinicians to better under-
stand their patient’s response and to adapt the therapeu-
tic strategy according to the host’s immune status.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P112
Cite this article as: Tanneau et al.: ImmunTraCkeR® as a reliable TCR
repertoire profiling tool to understand immune response and to explore
immunotherapy biomarkers. Journal for ImmunoTherapy of Cancer 2013
1(Suppl 1):P112.
ImmunID Technologies, Grenoble, France
Tanneau et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P112
http://www.immunotherapyofcancer.org/content/1/S1/P112
© 2013 Tanneau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
